Anidulafungin in Treating Immunocompromised Children With Neutropenia

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Neutropenia due to cytotoxic chemotherapy or aplastic anemia
• •* Duration expected to be 10 days
• •* Absolute neutrophil count less than 500/mm\^3 OR less than 1,000/mm\^3 and expected to fall below 500/mm\^3 within 72 hours
• •No deeply invasive fungal infection confirmed prior to study entry
• •PATIENT CHARACTERISTICS:
• •Age
• •2 to 17
• •Performance status
• •Not specified
• •Life expectancy
• •Not specified
• •Hematopoietic
• •See Disease Characteristics
• •Hepatic
• •AST or ALT no greater than 5 times upper limit of normal (ULN)
• •Bilirubin no greater than 2.5 times ULN
• •Renal
• •Creatinine clearance at least 30 mL/min
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective barrier contraception during and for at least 30 days after study participation
• •No prior anaphylaxis attributed to the echinocandin class of antifungals
• •No other concurrent medical condition that would preclude study participation
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •See Disease Characteristics
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •Not specified
• •Surgery
• •Not specified
• •Other
• •More than 4 weeks since prior investigational drugs
• •No prior participation in this clinical trial
• •No prior anidulafungin
• •No other concurrent investigational drugs
• •No other concurrent systemic antifungal agents (e.g., amphotericin, systemic azoles, or triazole antifungal agents)
• •* Concurrent oral, nonabsorbable azoles and topical antifungal agents (e.g., nystatin and/or azole formulations) allowed
• •Concurrent broad-spectrum antibiotics allowed